Categories
Change Password!
Reset Password!
Combined use of Diclofenac and Hyaluronate can be
used in osteoarthritis (OA) patients to improve the OA-related symptoms.
Diclofenac etalhyaluronate (DF-HA) intra-articular (IA) injections when
used every 4 weeks for an year were found to be
well-tolerated and safe implying to their long-term improvement in the
resolution of OA symptoms, concluded a study issued in BMC Musculoskeletal Disorders.
This
deduction was based on the multi-center, open-label, non-comparative phase 3
study comprising of 166 OA patients. These patients were administered with
DF-HA 30 mg IA injection for total 13 times i.e. at every 4 weeks for a year.
Therapy-emergent adverse events (TEAEs) and target joint structural changes and;
joint pain scores were regarded as the safety and efficacy outcomes. The
concomitant analgesics usage was not limited.
Out
of the total patients, 126 patients had knee OA and 40 patients were diagnosed
with other OA (shoulder, elbow, hip or ankle). About 75.9% patients witnessed
all TEAEs. The treatment period was not linked with the occurrence of
treatment-related TEAEs. At week 52 or at final assessment, no noteworthy
worsening of joint status was perceived. Mean joint pain scores were 5.9 ± 1.2,
4.9 ± 1.9, and 3.1 ± 2.3 at starting point, and weeks 2 and week 52. The pain
score improved after the first injection and sustained until week 52
irrespective of the type of OA.
As understood, DF-HA might be an effective therapy for OA patients.
BMC Musculoskeletal Disorders
Open-label phase 3 study of diclofenac conjugated to hyaluronate (diclofenac etalhyaluronate: ONO-5704/SI-613) for treatment of osteoarthritis: 1-year follow-up
Yoshihiro Nishida et al.
Comments (0)